Context Capital Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Context Capital Management’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-194,400	Closed	-$1.96M	–	453
2022 Q4	$1.96M	Hold	194,400	–	–	0.14%	161
2022 Q3	$1.93M	Buy	+194,400	New	+$1.92M	0.13%	212
2022 Q2	–	Sell	-194,400	Closed	-$1.92M	–	700
2022 Q1	$1.92M	Hold	194,400	–	–	0.12%	240
2021 Q4	$1.91M	Buy	+194,400	New	+$1.91M	0.15%	209

Context Capital Management's BIOT Position: Q1 2023 in Review

Context Capital Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 194,400 shares — an estimated $1.96M sold.

Context Capital Management first reported a position in BIOT in Q4 2021 and held it in 4 quarters. The position peaked at $1.96M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Context Capital Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Context Capital Management sold 194,400 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $1.96M.
Context Capital Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q4 2021 and held it in 4 quarters.
Context Capital Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $1.96M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Context Capital Management's 13F filing for Q1 2023, filed 8 May 2023.